Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.

Jupeng Yuan,Bo Li,Nasha Zhang,Hui Zhu,Liqing Zhou,Li Zhang,Ming Yang

Clinical Lung Cancer（2018）

引用 14|浏览10

暂无评分

摘要

Our results indicate that the BIM deletion polymorphism might be a promising germline biomarker for gefitinib treatment in Chinese patients with lung adenocarcinoma.

查看译文

关键词

Apoptosis,Drug resistance,EGFR-TKI,Genetic variant,Survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要